By Aaron Bloom

DocMJ is Florida’s largest and most experienced group of certified medical marijuana physicians. We have been providing appropriate medical marijuana recommendations to qualified patients since 2016. We are proud to offer our patients world-class care at an affordable price. All our physicians and mental health counselors are experienced experts who really understand the needs of patients who seek medical cannabis as an alternative to prescription drugs.

One of the things that sets DocMJ apart from other providers is that we work hard to understand the complete patient. We recognized early on that patients who suffer from some chronic anxiety conditions (e.g. PTSD), may need more than just medicinal relief. We know that research has shown that when you combine medical marijuana use with counseling, you not only treat the symptoms but also the underlying cause. For us, this is just a part of helping all patients have their own individual wellness journey with medical cannabis.

We have educational resources that are easily accessible via our website at www.docmj.com. Additionally, patients can feel connected by watching any of our numerous videos including patient testimonials, cannabis educational videos and blogs, and more. When it comes to medical cannabis, qualifying conditions, and positive treatment outcomes, DocMJ is a patient’s best alternative for their treatment journey. We have everything a patient needs under one amazing umbrella website that is easy to navigate and helps patients feel comfortable with medical cannabis.

Patients don’t have to suffer from chronic pain, anxiety, PTSD and a host of other qualified conditions in Florida. They can rely on DocMJ to help them learn everything they need to know about medical marijuana and most importantly, get the real relief they have been searching for.

Aaron Bloom is CEO at DocMJ. To learn more, visit www.docmj.com.




Do your patients suffer from chronic joint pain or mobility issues? Are you looking for a natural way to help them reduce inflammation and get relief without pharmaceuticals or NSAIDS? Are you looking for a high-quality product to offer at your practice for an additional, turn-key, income stream?

PūrWell’s medically focused products are custom formulated to help alleviate specific symptoms. This is nothing like any of the CBD products you see on Amazon or at your local gas station.

A prime example is PūrRelēf. PūrRelēf is an all-natural cannabinoid supplement (CBD + CBG + Delta-8 THC) that has been shown to reduce pain and aid mobility; even for stubborn, persistent conditions. Patients can finally receive all the relief that medical marijuana patients enjoy, without the need for a medical card!

What makes PūrRelēf stand out from the crowd?

  • Medical grade formula that is safe for daily use
  • USDA certified organic and pesticide free
  • No artificial colors, flavors, or sweeteners
  • Non-GMO
  • Alcohol Free
  • Gluten free
  • Vegan
  • Kosher
  • Powerful anti-inflammatory and antioxidant Flavonoids (Baicalin + Catechin)
  • Boswellia and Turmeric for additional anti-inflammatory support

Would you like to learn more about PūrRelēf? Contact one of PūrWell’s expert CBD Consultants to find out how your patients can start living with less pain and anxiety, the natural way. For more information, please visit www.purwell.com or call 844-PUR-WELL (787-9355).

 




By Dr. Jeff G. Konin

It is likely that if you are reading this article, you too have realized that we all have a long way to go in educating the general public about many aspects of cannabis. I have found that in near every presentation that I give it is essential to revert back to the basics. Why? The bottom line is that for the most part the general public is not cannabis smart. This may or may not include the hundreds of thousands of medical marijuana patients in Florida, but it is essential to elevate the baseline knowledge of as many people as possible in order to remove the remaining stigmas associated with cannabis.

Here is my top 10 list of cannabis myths and facts that should be a part of every educational presentation:

  1. CBD is a drug that can get you high. The majority of the general public do not know what cannabinoids are or that there is any difference between THC and CBD, let alone what the difference actually is. Very simple explanations, factoid sheets, and educational materials can go a long way toward clarifying this myth.
  1. There is no research to support any effectiveness of cannabis. The fact is if you type the word “cannabis” in a PubMed search it will yield 27,628 results! It that a lot? Yes. Could we benefit from more? Of course! It is important to disseminate what has been published with quality and strive to performs the studies that address the unanswered questions.
  1. CBD has a psychoactive effect. This is likely a result of people simply clumping “all things cannabis” together under one umbrella. It may or may not be too much to expect laypersons to understand terms like Dealta-8 versus Delta-9 but explaining the fact that THC-based products are the psychoactive components is not difficult to convey.
  1. CBD and THC can be taken in any dosage regardless of what other medications one uses. While there may be many benefits to the various cannabinoids, it is critical to emphasize that appropriate dosing with cannabis is just as important as it is with other prescribed or over-the-counter medications. As one would expect and hopefully understand, too little or too much may not achieve a desirable effect.
  1. All cannabis is the same. This goes without saying that the more we learn about the variations of the plant the more we need to educate others. For now, it is too easy for people to just think all cannabis is the same. One analogy I have used to begin this conversation is to think of the cannabis plant in the way you might think of a coffee bean. Coffee beans can grow in different geographies, under different climates, with different cultivation methods. All coffee beans are not the same.
  1. CBD will show up in a drug test. This may be one of the biggest fears that individuals have – the possibility of whatever cannabinoid they take and no matter how they take it – it will lead to a positive drug test. While there are no absolutes, and certainly there is inaccurate labeling or no labeling with some products, this is an area that needs further factual clarification and may in fact be specific to one’s occupation and what form of cannabis they are choosing to use in what manner.
  1. Cannabis can cure any condition. It can’t? Really? How about the irony that states can approve the use of medical marijuana for certain conditions, but over-the-counter CBD products are not allowed to market their benefit for any medical condition? The fact is that by the very nature of having receptors throughout the body leads to the claims of symptomatic relief for many. An explanation of how this works can be helpful without getting too technical, with a disclaimer that cannabis is not a cure all for everything.
  1. Medicinal and recreational marijuana are the same thing. This is an area where we as educators, healthcare providers, and clinicians can play a major role in explaining the importance of professional oversight, advice and guidance for using cannabis to obtain optimal results. The difference here lies in one’s purpose and goals.
  1. It is not possible that the body has a new system. Very few of us who have migrated to the cannabis space went to school during a time when we were formally educated about the endocannabinoid system. How is it possible that just 30 some years ago someone found a system in the body that we never knew about? Teaching an old dog new tricks is possible. New body system charts in all of our offices need to include the ECS alongside nervous, cardiovascular, digestive, etc.
  1. Cannabis is illegal. No not all cannabis is illegal all of the time. Educating here involves more than Florida laws. A good number of individuals flock here during the winter, vacation here and many of us from here travel elsewhere. Despite frequent changes in legislation, providing simple methods for people to understand what is legal, where it is legal, how it impacts travel, work and even possession are important.

 

Dr. Jeff G. Konin is a Clinical Professor in the Department of Athletic Training in the Nicole Wertheim College of Nursing and Health Sciences at Florida International University (FIU) where he directs the Global Initiative for Cannabinoid Research and Education. To learn more about FIU’s cannabinoid research and education initiative you can visit their website at https://go.fiu.edu/GlobalCannabis. Views represented in this column do not reflect that of Florida International University and are solely attributed to Dr. Jeff G. Konin.




U.S. Senate Majority Leader Chuck Schumer announced that he intends to formally introduce the Cannabis Administration and Opportunity Act (CAOA) in April. The forthcoming legislation, which was released in draft form last July, repeals federal marijuana prohibition by removing cannabis from the U.S. Controlled Substances Act.

Speaking at the event, Sen. Schumer said: “In the coming weeks, we’re ramping up our outreach and we expect to introduce final legislation. Our goal is to do it in April. Then we begin the nationwide push, spearheaded by New York, to get the federal law done. As the majority leader, I can set priorities. This is a priority for me.”

NORML’s Political Director Morgan Fox responded: “We are enthusiastic that the Senator is moving forward on his promise to prioritize cannabis policy reform in the 117th Congress. It is our hope that the official introduction of CAOA jumpstarts hearings and debates in the Upper Chamber — debates that are long overdue.”

In past months, Senate leadership has received criticism for both the slow rollout of the CAOA and for failing to support efforts to enact more incremental federal legislation, such as The SAFE Banking Act, which has been passed multiple times by the U.S. House of Representatives.

NORML was among numerous groups that submitted comments in response to CAOA draft. Specifically, NORML called for:

  • Strengthening civic protections, including record relief, to provide justice to those previously wronged by federal marijuana criminalization;
  • Revising outdated employment policies regarding non-scientific testing for trace metabolic elements of THC;
  • Ensuring that small and local businesses can compete both with larger corporations and the unregulated market by reducing regulatory and tax burdens;
  • Narrowing the scope of the proposed excise tax to exempt medical cannabis consumer markets;
  • Balancing the roles of the FDA, TTB, ATF, and antitrust regulators in a manner that is consistent with other adult-use substances, such as alcohol or tobacco, to ensure non-disruption of currently operational state programs and promoting increased local ownership in the future iterations of the marketplace.

As initially drafted, the Cannabis Administration and Opportunity Act directs the U.S. Attorney General to remove marijuana from the federal Controlled Substances Act — thereby allowing states to either maintain or establish their own cannabis regulatory policies free from undue federal interference. Under this scheme, state governments – if they choose to do so – can continue to impose criminal penalties for marijuana possession offenses. However, states would not be permitted to prohibit the interstate commerce of legal cannabis products transported through their borders.

The proposal also mandates for the expungement of the records of anyone convicted of a federal, non-violent marijuana offense. The expungements must take place within one year of the law’s enactment.

The Act also forbids federal officials from taking discriminatory actions against those who legally use cannabis. It prohibits “individuals from being denied any federal public benefit … on the basis of [the] use or possession of cannabis.” It also, for the first time, permits physicians associated with the U.S. Department of Veterans Affairs to make recommendations to their patients to access medical cannabis.

The proposal transfers primary agency jurisdiction over cannabis regulation from the U.S. Drug Enforcement Administration to the Food and Drug Administration and to the Alcohol and Tobacco Tax and Trade Bureau in manner similar to the ways in which these agencies already oversee alcohol and tobacco products. A federal excise tax of 10 percent would be imposed within the first year of the law’s enactment. Medical cannabis access programs, which are operational in the majority of U.S. states, would not be disrupted under this federal plan.

The proposed Senate plan is competing against two other House bills, The MORE Act and The States Reform Act, both of which also seek to deschedule cannabis at the federal level. The MORE Act previously was advanced by the U.S. House of Representative in the 116th Congress and is expected to be taken up again by House lawmakers in the coming weeks.




Cresco Labs Inc. is pleased to announce the opening of a new Sunnyside dispensary located at 505 NE 125th St. in North Miami. Sunnyside North Miami is Cresco Labs’ first location in Miami-Dade County, 15th store in the state and 49th dispensary nationwide.

 

“We’re pleased to continue expanding our retail presence in south Florida with the opening of Sunnyside North Miami,” said Cris Rivera, Florida Regional President at Cresco Labs. “We aim to normalize the cannabis buying experience and ensure that every patient feels comfortable buying cannabis products through our bright, open, welcoming stores and knowledgeable wellness advisors. Following the opening of Sunnyside Clearwater last week, or North Miami store will offer the same approachable and welcoming store experience and provide a wide selection of premium branded products and convenient next-day delivery service.”